anti-doping testing raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-25. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
== Hormone receptor antagonists == Hormone receptor antagonists bind to the normal receptor for a given hormone and prevent its activation. The target receptor may be on the cell surface, as in the case of peptide and glycoprotein hormones, or it may be intracellular, as in the case of steroid hormone receptors.
Part-time training was compulsory for all white males between 18 and 55, with a small number of exceptions for those in reserved occupations. On 25 May 1940 Southern Rhodesia, the last country to join the EATS, became the first to start operating an air school under it, beating Canada by a week. The SRAF was absorbed into the British Royal Air Force in April 1940, with No. 1 Squadron becoming No. 237 Squadron. The RAF subsequently designated two more Rhodesian squadrons, namely No. 266 Squadron in 1940 and No. 44 Squadron in 1941, in a manner similar to the Article XV squadrons from Australia, Canada and New Zealand.
The suspensory muscle of duodenum (also known as suspensory ligament of duodenum, Treitz's muscle or ligament of Treitz) is a thin muscle connecting the junction between the duodenum and jejunum (the small intestine's first and second parts, respectively), as well as the duodenojejunal flexure to connective tissue surrounding the superior mesenteric and coeliac arteries. The suspensory muscle most often connects to both the third and fourth parts of the duodenum, as well as the duodenojejunal flexure, although the attachment is quite variable. The suspensory muscle marks the formal division between the duodenum and the jejunum. This division is used to mark the difference between the upper and lower gastrointestinal tracts, which is relevant in clinical medicine as it may determine the source of gastrointestinal bleeding. The suspensory muscle is derived from mesoderm and plays a role in the embryological rotation of the gut, by offering a point of fixation for the rotating gut. It is also thought to help digestion by widening the angle of the duodenojejunal flexure. Superior mesenteric artery syndrome is a rare abnormality caused by a congenitally short suspensory muscle.
Sources: en.wikipedia.org
=== Dosing === The table below provides doses of major serotonergic psychedelics as well as the entactogen and mild psychedelic MDMA ("ecstasy") that have been determined on the basis of clinical studies. Other dosing schemes have also been reported.
== History == LFTs derive from paper chromatography, which was developed in 1943 by Martin and Synge, and elaborated in 1944 by Consden, Gordon and Martin. There was an explosion of activity in this field after 1945. The ELISA technology was developed in 1971. A set of LFT patents, including the litigated US 6,485,982 described below, were filed by Armkel LLC starting in 1988. The first commercially available lateral flow device was Unipath's Clearblue One Step in 1988. This product combined Paired Monoclonal Antibody technology (patented in 1980 by Unipath's Prof. Philip Porter and colleagues including Paul Davis and Keith May) and the original Clearblue product launched in June 1985.
Bulk materials (>100 nm in size) are expected to have constant physical properties (such as thermal and electrical conductivity, stiffness, density, and viscosity) regardless of their size, for nanoparticles, however, this is different: the volume of the surface layer (a few atomic diameters-wide) becomes a significant fraction of the particle's volume; whereas that fraction is insignificant for particles with a diameter of one micrometer or more. In other words, the surface area/volume ratio impacts certain properties of the nanoparticles more prominently than in bulk particles.
In September 1981, shortly after Mahathir assumed office as prime minister, the country carried out the "Dawn Raid", a calculated operation orchestrated by Permodalan Nasional Berhad (PNB) to regain majority ownership of Guthrie, one of the largest British-owned plantation companies at the time. This move symbolized a broader effort under Mahathir's leadership to reduce foreign dominance over Malaysia's economy and reclaim control of national assets. A month after the Dawn Raid, Mahathir introduced the "Buy British Last" (BBL) policy, which lasted from October 1981 to March 1983. The reason for this policy was rooted in several grievances with Britain. Britain's decision to abolish tuition fee subsidies for Commonwealth students placed a heavy financial burden on Malaysia, which had to cover the increased costs for approximately 17,000 Malaysian students studying in the UK. Additionally, British media criticism of Malaysia's internal policies further strained relations. The BBL policy, which directed government ministries and agencies to deprioritize British goods and services, significantly affected Britain, causing estimated losses of between £15.5 million and £50 million in the early months. This eventually led to negotiations, culminating in Mahathir and British Prime Minister Margaret Thatcher meeting in 1983 to resolve the tensions and end the policy. Mahathir later recalled persuading Thatcher that raising tuition fees was a mistake, leading Thatcher to introduce scholarships for Malaysian students.
Sources: en.wikipedia.org
== Selection and training == From early 1978 to 1980, support, training, and selection consisted of 3 phases, culminating latterly in 6 months/24 weeks training, with the first phase lasting as long as 11 weeks (the RLI's first phase was 6 weeks). Emphasis in selection depended on extreme physical fitness and aggression (running at an excess of 120 kilometres per week), mental strength in decision making and problem solving under extreme duress. The selection course consisted of a junior leader assessment in all areas concerning leadership. All Counter Operations Insurgency (COIN) battle drills were held in battle camps at Concession and Shamva. The pass rate among recruits amounted to only 30%. On passing out, recruits were deployed to one of 13 and latterly 14 troops (Troop company strength being 120 men; Mantle Mounted and November Troop being new additions in 1981). The Support Unit supported the Police in rural problem areas (latterly dissidents), as well as in urban emergencies. In November 1980, during the Entumbani I uprising, two sections of 60 men each from 5 Support Unit Troops (Mantle Echo, Mantle Charlie, Mantle Juliet, Mantle Hotel, Mantle Lima, 300 men in all), travelled from all over Zimbabwe to reach Bulawayo in 11 hours. Due to the Support Unit Troops being independent with their own vehicles, stores, ammunition, medical supplies, tents etc., they could deploy anywhere at a moment's notice all over Zimbabwe.
=== Diet === People with autoimmune hyperthyroidism (such as in Graves' disease) should not eat foods high in iodine, such as edible seaweed and seafood. From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower rates of disease and goiters, and improved the lives of children whose mothers would not have eaten enough iodine during pregnancy, which would have lowered the IQs of their children.
Three more recent reviews reached similar conclusions: little evidence supporting the use of trigger point dry needling to treat upper shoulder pain and dysfunction, evidence not robust enough to draw a clear conclusion about safety and efficacy, and that dry needling for the treatment of myofascial pain syndrome in the lower back appeared to be a useful addition to standard therapies, but stated clear recommendations could not be made because the published studies were small and of low quality. However, a retrospective analysis of 2,910 dry needling interventions as reported by Mabry, et al. identified no reported safety events when dry needling was performed by physical therapists.
This will continue, until both flows reach a similar dilution, with a concentration somewhere close to midway between the two original dilutions. Once that happens, there will be no more flow between the two tubes, since both are at a similar dilution and there is no more osmotic pressure.
=== Triacidic bases === When one molecule of base via complete ionization produces three hydroxide ions, the base is said to be triacidic or triprotic. Examples of triacidic bases are: Aluminium hydroxide, ferric hydroxide, gold(III) hydroxide.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.